Your institution may have access to this item. Find your institution then sign in to continue.
Title
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU).
Authors
Marre, M.; Shaw, J.; Brändle, M.; Bebakar, W. M. W.; Kamaruddin, N. A.; Strand, J.; Zdravkovic, M.; Le Thi, T. D.; Colagiuri, S.